Lantheus Holdings, Inc. (NASDAQ: LNTH)

Lantheus Holdings, Inc. is a radiopharmaceutical focused company that enables clinicians to find, fight, and follow disease to improve patient outcomes. The company is headquartered in Massachusetts and maintains offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom.

Lantheus generates revenue primarily from the sale of its radiopharmaceutical products, including PYLARIFY for prostate cancer imaging, DEFINITY for ultrasound enhancement, and Neuraceq for amyloid PET imaging, as well as from licensing agreements, royalties, milestone payments, and contract development and manufacturing organization services provided through its Evergreen subsidiary. The company sells its products throughout the United States to hospitals, independent imaging centers and government facilities, and distributes internationally through direct and third party arrangements in Europe, Canada, Asia Pacific, Latin America and other regions.

The company operates through the following segments: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.

• Radiopharmaceutical Oncology: This segment focuses on PYLARIFY, an FDA approved PET imaging agent that targets prostate specific membrane antigen, and includes related oncology pipeline candidates aimed at detecting and monitoring cancer. The product is distributed through a network of radiopharmacies and is used in PET/CT procedures to detect and monitor metastatic disease.

• Precision Diagnostics: This segment provides DEFINITY, an ultrasound enhancing agent used to improve echocardiogram images, and Neuraceq, a PET imaging agent that binds to beta amyloid plaques in the brain to aid in Alzheimer’s disease assessment. DEFINITY is used in adult and pediatric patients with suboptimal echocardiograms, while Neuraceq supports clinicians in estimating amyloid burden and selecting patients for anti amyloid therapy.

• Strategic Partnerships and Other Revenue: This segment includes biomarker solutions such as MK 6240 and NAV 4694, digital solutions like aBSI and aPROMISE, contract development and manufacturing operations from Evergreen, and licensing agreements that generate royalties and milestone payments from partners such as GE Healthcare. The biomarker programs support clinical trials for Alzheimer’s disease and oncology, while the digital tools provide AI powered image analysis for prostate cancer and bone scans.

Lantheus holds a leading position in the radiopharmaceutical industry, competing with companies such as Telix Pharmaceuticals, Blue Earth Diagnostics (a Bracco subsidiary), GE Healthcare, and Eli Lilly. Its competitive advantages stem from a proprietary product portfolio, a strong patent pipeline, a reliable network of radiopharmacies for production and distribution, and its integrated CDMO capabilities that support both internal programs and external partners. The company also benefits from a diversified revenue base that spans diagnostic imaging, therapeutic development, and contract manufacturing services.

Lantheus serves hospitals, independent imaging centers, and government facilities in the United States, and reaches international markets through distributors in Europe, Canada, Asia Pacific, and other regions. Its products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists. The company also collaborates with academic medical centers and research institutions that utilize its radiopharmaceuticals in clinical studies and development programs.